(Q38497958)

3 September 2017

1 reference

title

Emerging therapies: angiogenesis inhibitors for ovarian cancer (English)

1 reference

3 September 2017

1 reference

angiogenesis inhibitor

1 reference

Amanda L Jackson

1

1 reference

3 September 2017

Eric L Eisenhauer

series ordinal

2

1 reference

3 September 2017

Thomas J Herzog

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 June 2015

1 reference

Expert Opinion on Emerging Drugs

3 September 2017

published in

1 reference

3 September 2017

volume

20

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

331-346

1 reference

3 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Cost-utility of initial medical management for Crohn's disease perianal fistulae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1036739

10.1517/14728214.2015.1036739

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference